Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

20.70USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$20.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
73,755
52-wk High
$37.45
52-wk Low
$19.62

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $842.90
Shares Outstanding(Mil.): 30.82
Dividend: --
Yield (%): --

Financials

  RVNC.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -3.43 -- --
ROI: -50.65 9.01 14.96
ROE: -52.67 10.15 16.52

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Dec 04 2018

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Dec 04 2018

Revance Therapeutics' frown lines treatment succeeds in late-stage trial

Dec 4 Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

Dec 04 2018

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Sep 14 2018

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Sep 14 2018

Earnings vs. Estimates